Testing effectiveness (Phase 2)Ended earlyNCT05215951What this trial is testingOsimertinib Plus Chemotherapy in Uncommon EGFRm NSCLCWho this might be right forLung Cancer AstraZeneca 4
Large-scale testing (Phase 3)Study completedNCT03206151What this trial is testingCMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal CancerWho this might be right forMetastatic Colorectal Cancer Taizhou Mabtech Pharmaceutical Co.,Ltd 520
Testing effectiveness (Phase 2)Active Not RecruitingNCT05466149What this trial is testingEfficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 InsertionWho this might be right forNSCLC Allist Pharmaceuticals, Inc. 100
Testing effectiveness (Phase 2)Ended earlyNCT02720185What this trial is testingWindow of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFRWho this might be right forBreast NeoplasmsTriple Negative Breast Neoplasms University of Wisconsin, Madison 5
Early research (Phase 1)UnknownNCT02211443What this trial is testingSafety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal CancerWho this might be right forMetastatic Colorectal Cancer Sinocelltech Ltd. 21
Not applicableStudy completedNCT05709158What this trial is testingLearn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)Who this might be right forBreast Cancer Pfizer 4,184
Early research (Phase 1)Looking for participantsNCT04913285What this trial is testingEvaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsWho this might be right forSolid Tumor, AdultNon-small Cell Lung CancerMelanoma Pierre Fabre Medicament 400
Not applicableUnknownNCT05560035What this trial is testingThe Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer SurgeryWho this might be right forCervical CancerMetastatic Cancer General Hospital of Ningxia Medical University 60
Not applicableStudy completedNCT06119347What this trial is testingAcute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint InhibitorsWho this might be right forAKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs First Affiliated Hospital of Wenzhou Medical University 1,581
Testing effectiveness (Phase 2)Ended earlyNCT02095782What this trial is testingChemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor MutationWho this might be right forNon-small-cell Lung Cancer Guangdong Association of Clinical Trials 10
Early research (Phase 1)Ended earlyNCT03284723What this trial is testingPF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid TumorsWho this might be right forBreast Neoplasms Pfizer 95
Testing effectiveness (Phase 2)Study completedNCT02970682What this trial is testingSFX-01 in the Treatment and Evaluation of Metastatic Breast CancerWho this might be right forBreast Neoplasm Evgen Pharma 60
Early research (Phase 1)UnknownNCT02321293What this trial is testingProspective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLCWho this might be right forLung Cancer Lady Davis Institute 20
Testing effectiveness (Phase 2)Ended earlyNCT01918306What this trial is testingGDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast CancerWho this might be right forEstrogen Receptor Negative Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastTriple Negative Breast Cancer+3 more Vanderbilt-Ingram Cancer Center 11
Testing effectiveness (Phase 2)Study completedNCT02289833What this trial is testingTrastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Who this might be right forNon-Small Cell Lung Cancer Hoffmann-La Roche 49
Early research (Phase 1)Study completedNCT00444015What this trial is testingPhase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)Who this might be right forNon-Small-Cell Lung Carcinoma H. Lee Moffitt Cancer Center and Research Institute 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT05526755What this trial is testing5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)Who this might be right forStage II-IIIB Non-small Cell Lung Carcinoma AstraZeneca 188
Testing effectiveness (Phase 2)Study completedNCT00682383What this trial is testingCombined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)Who this might be right forUnresectable Locally Advanced NSCLC Mt. Sinai Medical Center, Miami 26
Testing effectiveness (Phase 2)Ended earlyNCT02192697What this trial is testingAn Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) MutationsWho this might be right forNon-small Cell Lung Cancer Astellas Pharma Inc 124
Testing effectiveness (Phase 2)Study completedNCT00875979What this trial is testingTrastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received TrastuzumabWho this might be right forMetastatic Breast Cancer Hoffmann-La Roche 67